Flexible Hybrid Electronic Platform for Sleep Monitoring with a Continuous Positive Airway Pressure Monitoring (CPAP) Device

持续气道正压通气（CPAP）是治疗阻塞性睡眠呼吸暂停（OSA）的金标准。牙科器具，这是体积小于CPAP设备，可以规定为OSA。然而，它们并不像CPAP设备那样对OSA患者有效。该项目的目的是设计、开发和评估一个灵活的混合睡眠监测平台，该平台可以与CPAP设备集成。监测系统将包括印刷CO2传感器、光电体积描记器（PPG）传感器和用于加速度计、电源管理、信号调节、处理和通信的传统硅集成电路（IC）。柔性混合电子器件的使用将联合收割机将硅IC的处理和存储能力与印刷和有机电子器件的灵活性和成本效益结合起来。该系统将允许测量生理参数;潮气末CO2、血氧饱和度、心率和呼吸以及加速度计，以检测睡眠潜伏期、开始和持续时间。为患者提供智能CPAP将有助于iMD Research和Object Research Systems在生产的前36个月内获得预计12%的魁北克CPAP市场份额。该项目的成功完成将导致两个行业合作伙伴在员工数量、知识产权产生、保留和销售方面的增长。在智能CPAP设备的帮助下，医疗保健提供者将能够定期记录CPAP用户的睡眠，更准确地评估治疗的有效性，并在必要时及时重新调整CPAP。因此，未治疗的OSA病例数量将减少。这将反过来减少与未治疗的OSA相关的经济损失。记录CPAP用户的睡眠数据将使加拿大处于睡眠呼吸暂停研究和治疗的最前沿。最后，该项目开发的低成本柔性印刷和有机传感器将有助于降低其他医疗设备的成本，并将为行业合作伙伴提供可穿戴行业的市场份额。

Continuous positive airway pressure (CPAP) device is a gold standard treatment for Obstructive sleep apnea (OSA). Dental appliances, which are less bulky than CPAP device, can be prescribed for OSA. However, they are not effective for everyone with OSA like the CPAP device. The aim of the project is to design, develop and evaluate a flexible hybrid sleep monitoring platform that can be integrated with a CPAP device. The monitoring system will consist of printed CO2 sensor, photoplethysmograph (PPG) sensor, and conventional silicon integrated circuits (ICs) for accelerometer, power management, signal conditioning, processing and communications. Use of flexible hybrid electronics will combine the processing and storage capabilities of silicon ICs with the flexibility, and cost benefits of printed and organic electronics. The system will allow measurement of physiological parameters; end-tidal CO2, blood oxygen saturation, heart rate and breathing as well as accelerometry to detect sleep latency, onset and duration. Providing patients with the smart CPAP will help iMD Research and Object Research Systems acquire a projected 12% of Quebec CPAP market share within the first 36 months of production. Successful completion of the project will result in growth of the two industry partners in terms of number of employees, IP generated, kept and sold by them. With the help of smart CPAP device the healthcare providers will be able to document the CPAP users' sleep on a regular basis, evaluate the effectiveness of the treatment more accurately and retitrate the CPAP if necessary on time. Thus, there will be a decrease in the number of untreated OSA cases. This will in turn reduce the economic loss related with untreated OSA. Documenting the sleep data on CPAP users will put Canada in the forefront of sleep apnea research and treatment. Finally, the low cost flexible printed and organic sensors developed in the project will help to reduce the cost of other medical devices and will provide industry partners a market share in wearable industry.